Biophytis (France) Performance
| ALBPS Stock | EUR 0.30 0.01 3.45% |
The firm shows a Beta (market volatility) of 2.77, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Biophytis will likely underperform. At this point, Biophytis SA has a negative expected return of -0.98%. Please make sure to confirm Biophytis' potential upside, as well as the relationship between the rate of daily change and relative strength index , to decide if Biophytis SA performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Biophytis SA has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in December 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
| Begin Period Cash Flow | 5.8 M | |
| Total Cashflows From Investing Activities | 12.2 M |
Biophytis |
Biophytis Relative Risk vs. Return Landscape
If you would invest 60.00 in Biophytis SA on August 28, 2024 and sell it today you would lose (30.00) from holding Biophytis SA or give up 50.0% of portfolio value over 90 days. Biophytis SA is generating negative expected returns and assumes 4.4018% volatility on return distribution over the 90 days horizon. Simply put, 39% of stocks are less volatile than Biophytis, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Biophytis Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biophytis' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Biophytis SA, and traders can use it to determine the average amount a Biophytis' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2227
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ALBPS |
Estimated Market Risk
| 4.4 actual daily | 39 61% of assets are more volatile |
Expected Return
| -0.98 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.22 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Biophytis is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biophytis by adding Biophytis to a well-diversified portfolio.
Biophytis Fundamentals Growth
Biophytis Stock prices reflect investors' perceptions of the future prospects and financial health of Biophytis, and Biophytis fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biophytis Stock performance.
| Return On Equity | -6.81 | |||
| Return On Asset | -0.51 | |||
| Current Valuation | (498.56 K) | |||
| Shares Outstanding | 203.97 M | |||
| Price To Earning | (4.45) X | |||
| Price To Book | 1.62 X | |||
| EBITDA | (26.5 M) | |||
| Cash And Equivalents | 7 M | |||
| Cash Per Share | 0.83 X | |||
| Total Debt | 6.29 M | |||
| Debt To Equity | 442.80 % | |||
| Book Value Per Share | 0.02 X | |||
| Cash Flow From Operations | (23.8 M) | |||
| Earnings Per Share | (0.19) X | |||
| Total Asset | 36.26 M | |||
About Biophytis Performance
Assessing Biophytis' fundamental ratios provides investors with valuable insights into Biophytis' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Biophytis is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. The company was founded in 2006 and is headquartered in Paris, France. BIOPHYTIS operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 30 people.Things to note about Biophytis SA performance evaluation
Checking the ongoing alerts about Biophytis for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biophytis SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biophytis SA generated a negative expected return over the last 90 days | |
| Biophytis SA has some characteristics of a very speculative penny stock | |
| Biophytis SA has high historical volatility and very poor performance | |
| Biophytis SA has high likelihood to experience some financial distress in the next 2 years | |
| Biophytis SA has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Net Loss for the year was (31.25 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Biophytis SA has accumulated about 7 M in cash with (23.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.83, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Biophytis' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biophytis' stock is overvalued or undervalued compared to its peers.
- Examining Biophytis' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biophytis' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biophytis' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biophytis' stock. These opinions can provide insight into Biophytis' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Biophytis Stock Analysis
When running Biophytis' price analysis, check to measure Biophytis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biophytis is operating at the current time. Most of Biophytis' value examination focuses on studying past and present price action to predict the probability of Biophytis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biophytis' price. Additionally, you may evaluate how the addition of Biophytis to your portfolios can decrease your overall portfolio volatility.